A Multicenter, Open-Label, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With Metastatic Castration-Resistant Prostate Cancer
Latest Information Update: 21 Oct 2024
At a glance
- Drugs YL 201 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors MediLink Therapeutics
Most Recent Events
- 12 Mar 2024 Status changed from not yet recruiting to recruiting.
- 09 Feb 2024 New trial record